Since the publication of this article, the authors became aware of a number of errors which were missed at proof stage:
In Fig. 1b the image for MCF7 (previously labelled MDA-MB-231) was incorrect and has been replaced.
In Supplementary Fig. 1 the graph for MCF7 (previously labelled MDA-MB-231) was incorrect and has been replaced.
In Figs. 1d and 4a , the western blot images for Tubulin ( Fig. 1a ) and HA (Fig. 4a) were not correct and have been replaced.
In Fig. 3a , the western blot image was not correct. The authors mistakenly used the MDA-MB-231, HBLIOO and HS578T image instead of the MCF7/13, HBLIOO/13 and MDA-MB-231/13 image. The image has been replaced.
All corrected figures are included below. The results and conclusions of this article are not affected by these modifications. The authors apologise to readers for any inconvenience caused.
The original article can be found online at https://doi.org/10.1038/onc. 2015.214. The WT and I3 cells of MCF7, HBL100 and MDA-MB-231 were treated with MG132 for 12 h and immunoprecipitated (IP) HSPA5 to detect ubiquitination of HSPA5. c MCF7/WT and MCF7/I3 cells were treated with or without proteasome inhibitor MG132 (5 μM) for 12 h, and HSPA5 protein expression was detected by western blot analysis. d MCF7/WT and MCF7/I3 cells were treated with 20 μg/ml cycloheximide (CHX) for indicated time points, and then detect HSPA5 protein expression by western blot analysis. e Western blot analysis of HSPA5 expression and the measurement of the migration and invasion abilities were measured by transwell assays in HSPA5-overexpressing MCF7 cells (left) and knockdown of HSPA5 in MCF7/I3 cells (right). Data are shown as mean ± s.d. of three independent experiments performed in triplicate. *P = 0.05; **P = 0.01; ***P = 0.001 Fig. 3 GP78 regulates cell migration/invasion through HSPA5 ubiquitination at K447. a MCF7, HBL100 and MDA-MB-231 cells were transfected with HA-tagged GP78 expression vector, and the expression of HA-GP78 and HSPA5 was confirmed by western blot analysis. b Determination of the protein stability of HSPA5 in MCF7/I3, MCF7/ WT, MCF7/WT/shctrl and MCF7/WT/shGP78 cells. Cells were treated with 20 μg/ml cycloheximide (CHX) for the indicated time, followed by western blot analysis. This was quantified by ImageJ system (Bethesda, MD, USA) and normalized to 0 h control. **P = 0.01; ***P = 0.001. Data are shown mean ± s.d. of three independent experiments performed in triplicate. c MCF7 cells were transfected with shGP78 and shcontrol (shctrl) and submitted for western blot analysis (left) of HSPA5 expression and the measurement of the migration and invasion abilities by transwell assays (right). Data are shown as mean ± s.d. of three independent experiments performed in triplicate. **P = 0.01; ***P = 0.001. d MCF7/shctrl and MCF7/ shGP78 cells were transfected with shHSPA5 and shctrl and submitted for western blot analysis (left) of HSPA5 expression and the measurement of the migration and invasion abilities by transwell assays (right). Data are shown as mean ± s.d. of three independent experiments performed in triplicate. *P = 0.05; **P = 0.01; ***P = 0.001. e Representative bioluminescent images and quantification of lung colonization in mice injected with MDA-MB-231/shctrl, MDA-MB-231/shGP78, MDA-MB-231/shGP78/shctrl and MDA-MB-231/ shGP78/shHSPA5 cells (six mice per group). Lung colonization was bioluminescently imaged after 8 weeks of injection. Data are shown as mean ± s.e.m. of a minimum of six animals (**P = 0.01). f HeLa cells were transfected with HSPA5-MYC/WT or HSPA5-MYC/K447A alone and in combination with HA-GP78 or vector control, and then the expression of HA-GP78 and HSPA5-MYC was confirmed by western blot analysis. g HeLa cellswere transfected with the indicated constructs and treated with MG132 for 12 h. Total cell lysates were harvested and ubiquitination of HSPA5 was analyzed by immunoprecipation and western blot analysis 
